iPRECIO Programmable Minipumps for better Predictivity

Important News – Incompatible Analgesic containing MCT Oil We have found that Ethiqa XR long acting analgesia which contains MCT oil is not compatible with iPRECIO pumps. The use of Ethiqa XR as analgesic has been found to weaken iPRECIO pump reservoir and cause leaks. More significant damage has also occurred. We recommend not to use Ethiqa XR or any analgesic formulations containing oils. If the use of Ethiqa XR is important, please contact Primetech Corporation for further information.   Finally, as a reminder, iPRECIO Pumps are not compatible with oils as vehicle and oils will weaken and will destroy the reservoir and catheter. Compatible vehicle or solvent list can found on the page page of iPRECIO Highlights. #3rs #implantablepumps #preclinical #drugdiscovery #compatibility

We are looking for a Scientist to join our Preclinical Translational Sciences team to support our broader Parkinson’s disease portfolio. If you’re interested in joining our team and have prior experience with rodent models of Parkinson’s disease, please apply! https://lnkd.in/guA6BCqt

Pump Programming: iPRECIO SMP-200 micro-infusion pumps were implanted in female Sprague Dawley rats at postnatal day 60 (P60). After a one-week recovery period post-implantation, pumps delivered morphine or saline in a scheduled regimen: Initial dosing of 10 mg/kg/day in three doses, incrementally increasing weekly by 2 mg/kg/day, up to 16 mg/kg/day. On approximately embryonic day 18 (E18), dosing frequency was reduced to twice daily, mitigating respiratory depression in pups observed in earlier experiments. Morphine exposure continued through gestation, tapering off by postnatal day 7 (P7). Here is original discussion https://lnkd.in/gk3aba9u #drugdelivery #translationalresearch

OPEN ACCESS - Drug Hunter 2024 M&A Review: Part 1 - Industry Overview | https://lnkd.in/duDJ4szz Drug Hunter has sifted through news articles, press releases, financial disclosures, SEC filings, and more to bring you a roundup of 2024’s biggest M&As in the drug discovery world. As part of this five-part series, we bring you an open-access overview of the M&A landscape, and then for Drug Hunter members in the coming weeks, we will be providing in-depth coverage and analysis of the small molecule-focused deals (parts 2 & 3), as well as those centered around biologics-based assets (parts 4 &5). This premium content will include background on the targets, chemical/biological matter, and the clinical data driving these deals. Read it on Drug Hunter | https://lnkd.in/duDJ4szz

Free Online Event: The Antimicrobial Chemotherapy Conference is taking place 4 & 5 February 2025. This open-access, virtual conference is jointly organised by BSAC and Global Antibiotic R&D Partnership (GARDP). Please help us spread the word! https://lnkd.in/dRQqHJwJ

Wonderful opportunity at ORIC to join our team!

Sharing here our mansucript published in Molecular Pharmaceutics about the factors affecting the clearance and biodistribution of polymeric nanoparticles. Still one of the most cited paper in Molecular Pharmaceutics and happy to respond to your questions about nanoparticles in vivo studies.

🧑🔬💊 We need to talk more biopharma R&D productivity this year 📊💡 My take on the fresh "special collection" on this topic from McKinsey & Company 📍 Big picture is spot on: Biopharma's innovation challenges remain, and return on investment on drug R&D continues to be under pressure 📍 The obvious: McK putting out a "special collection" of 100+ pages on R&D productivity at the start of 2025 just shows that they know biopharma is struggling to tackle these challenges 🧩 The R&D productivity equation is a composite of 5 levers: 👉 Pipeline volume 📍 The total, global pipeline is growing - trend: ↗️ (at least there is volume in the pipelines...great, as long as there is QUALITY, too) 👉 Probability of success 📍 PoS has not improved meaningfully over several decades - trend: ➡️ (McK puts it as ↘️, so I am a bit less pessimistic on this one; again, depends somewhat on dataset) 👉 Value per drug 📍 Peak sales per asset is under pressure, but let's go with McK here and say it is stable - trend: ➡️ 📍 Note that biopharma is increasingly relying on the "blockbuster model" (big wins make the day and make the wheels go round to pay for all your pipeline attrition and for the significant fraction of your drug launches that ends up with a negative ROI) 👉 R&D cost per drug 📍 Not getting cheaper to do drug R&D - trend: ↗️ (pharma R&D is now in the range of $250 billion per year) 👉 R&D speed (cycle times across R&D stages) 📍 McK states speed is increasing, but - again depends on dataset - I think this is too optimistic, so I would not put trend better than flat: ➡️ 🤕 ...and across the industry, these key levers are moving in "opposite" direction with the effect that positive and negative movements in the levers *cancel out*, muting any substantial and meaningful uptick in R&D productivity (it is like the industry is trying to address some levers, but then give away all the improvement to other levers) 📍 Where biopharma stands on R&D productivity today: Following decades of decline, we saw - looking at some metrics - signals from ~2010 that R&D productivity was starting to switch direction; however, the uptick has been erratic - with no convincing evidence that the industry is really on the right track Two other insights to take away: 🏃♀️➡️ Pharma pipelines are increasingly chasing the same targets - not a new phenomenon, but a reminder that no easy "blue ocean" strategy exists in this business (good luck competing in "red ocean") 🌀 Biopharma pipelines are extremely dynamic with an annual turnover of 20+% due to program discontinuation - it's a formidable task to replenish a fifth of your pipeline ... EVERY year! ❓ Curious to know what you think about biopharma R&D productivity anno 2025? ❓What are the conversations to have - and actions to take? Check out the special collection from McK: https://lnkd.in/dmKHjc5A #Biopharma #Productivity #DrugDevelopment

Been trying out Blinkist AI by Blinkist Blinkist AI Summarize web pages, videos, podcasts, or documents, then ask Blinkist AI follow-up questions to go even deeper! You can read it here or you can also listen to it. https://lnkd.in/gEQ-5BP7 What's in it for me? Imagine transforming the way drugs are administered in animal research. iPRECIO programmable pumps offer a solution that ensures precise, stress-free dosing for animals, ushering in new standards for preclinical trials. With the potential to improve research accuracy and welfare, this innovative technology is reshaping how compounds are delivered and measured in medical studies. If you're curious about the latest advancements in drug delivery methods and how they are enhancing research outcomes while reducing stress in animal models, this summary provides all the essential insights. Original Article Shared. Programmable pumps offer precise and translatable delivery of compounds to stress-free animals https://lnkd.in/gX78s5ht #drugdelivery #drugdiscovery #blinkist

Come join us in Small-Molecule Drug Discovery Chemistry at Genentech! If you're a PhD with 0-6 years experience and interested in #medicinalchemistry, submit an application through the link or reach out to me directly.